Design Therapeutics, Inc.
DSGN
$10.30
-$0.74-6.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -7.98% | -7.30% | |||
| Gross Profit | 7.98% | 7.30% | |||
| SG&A Expenses | 0.47% | -19.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.91% | -10.47% | |||
| Operating Income | 5.91% | 10.47% | |||
| Income Before Tax | 5.88% | 10.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.88% | 10.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.88% | 10.93% | |||
| EBIT | 5.91% | 10.47% | |||
| EBITDA | 5.97% | 10.56% | |||
| EPS Basic | 8.71% | 11.08% | |||
| Normalized Basic EPS | 8.74% | 11.11% | |||
| EPS Diluted | 8.71% | 11.08% | |||
| Normalized Diluted EPS | 8.74% | 11.11% | |||
| Average Basic Shares Outstanding | 3.13% | 0.16% | |||
| Average Diluted Shares Outstanding | 3.13% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||